A three-year, $689,000 grant from the Bristol Myers Squibb Foundation will enable teams from Roswell Park Comprehensive Cancer Center and the University of New Mexico to collaborate on health navigation services serving the people of the Pueblo Nations.
Adults who used e-cigarettes daily and also smoked combustible cigarettes were more likely to quit smoking than those who smoked but used e-cigarettes less frequently, new research from Roswell Park shows. The findings suggest that daily e-cigarette use may help some people to quit using combustible cigarettes.
The FDA has expanded orphan drug designation for SurVaxM, a brain cancer immunotherapy born in the labs of Roswell Park Comprehensive Cancer Center. The supplemental designation applies to SurVaxM as treatment for not just adult glioblastoma but any malignant glioma in children or adults.
Research by Hemn Mohammadpour, DVM, PhD, and colleagues at Roswell Park Comprehensive Cancer Center offers new insights into tumor biology and may lay the groundwork for more effective cancer immunotherapy. Their preclinical findings were published today in the journal Cellular & Molecular Immunology.
Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center - a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.
Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).
Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.
New insights on improving clinical outcomes and quality of life among breast cancer patients highlight the slate of new research presentations Roswell Park Comprehensive Cancer Center experts will deliver at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place in Chicago next week.
Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.”
A preclinical study led by a team of researchers at Roswell Park Comprehensive Cancer Center highlights the potential of a novel two-drug treatment strategy targeting p53-mutant cancers.
Up to 30% of patients newly diagnosed with acute myeloid leukemia (AML) have an FLT3 gene mutation, which is associated with a high risk of relapse and a very poor prognosis.
A research study led by a multidisciplinary team of scientists at Roswell Park Comprehensive Cancer Center details evidence on the therapeutic efficacy of a compound that targets a key genetic feature of pancreatic cancer.
As new cancer treatments become available, some of the most important ongoing research must look at ways to optimize those new approaches so that more patients can benefit from groundbreaking therapies.
The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to Canget BioTekpharma LLC for FL118, a drug candidate developed at Roswell Park Comprehensive Cancer Center, as a possible treatment for pancreatic cancer.
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.
Three physician-scientists who have relocated to Buffalo, New York, to join Roswell Park Comprehensive Cancer Center will apply highly specialized transplantation and cell therapy (TCT) expertise to both patient care and the development of New York State’s first cell therapy manufacturing and research hub. Brian Betts, MD, has joined Roswell Park as Vice Chair of Strategic Initiatives within the Transplant & Cellular Therapy Section, Department of Medicine; Kanwaldeep Mallhi, MD, was named Associate Professor of Oncology and Clinical Director of Pediatric Transplantation and Cellular Therapy in the Department of Pediatrics; and Shernan Holtan, MD, will join the Roswell Park faculty in February as Chief of Blood and Marrow Transplant in the Department of Medicine.
A phase 1 clinical trial conducted exclusively at Roswell Park Comprehensive Cancer Center shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC).
While the incidence of colorectal cancer (CRC) has dropped significantly among older adults in recent years — a trend attributed to regular screening colonoscopies and lower smoking rates — the opposite is true for people born between 1981 and 1996, who have double the risk compared with people born in 1950. There’s an urgent need to identify more-effective therapies for those younger people: Approximately 58% of patients age 50 or under have advanced, distant disease at the time of diagnosis, and only 14% of that group will survive five years.
An observational cohort study out of Roswell Park Comprehensive Cancer Center demonstrates that race and ethnicity affect a woman’s 21-gene recurrence score, a tool used to determine risk of recurrence and distant metastasis in patients with early-stage, hormone-receptor-positive breast cancer. Based on the expression of 21 cancer-related genes detected in pre-treatment tumor specimens, recurrence score is used routinely in clinical care to identify patients who might benefit from chemotherapy as part of their treatment plan. Scores range from 0-100, with a score of 26 or higher indicating greater risk of recurrence and poorer overall survival.
Research has shown that the immune system doesn’t function properly in patients with multiple myeloma, a blood cancer that occurs when plasma cells — a type of white blood cell — multiply out of control. But a clinical trial led by Jens Hillengass, MD, PhD, Chief of Myeloma at Roswell Park Comprehensive Cancer Center, shows that exercise may have the power to strengthen the immune system in those patients, providing a non-pharmaceutical method of helping control the disease.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right